文献速递骨肌介入MRCTUS

磁共振引导聚焦超声与经皮热消融治疗骨寡转移局部控制比较:系统综述与Meta分析

Magnetic resonance-guided focused ultrasound versus percutaneous thermal ablation in local control of bone oligometastases: a systematic review and meta-analysis.
PubMed 文献 · Radiol Med · 2024-02-02

该系统综述与Meta分析纳入24篇文章,比较MRgFUS与经皮热消融治疗骨寡转移的局部肿瘤控制率和并发症率。MRgFUS汇总局部肿瘤控制率为84%(95%CI 66-97%,I²=74.7%),经皮热消融为65%(95%CI 51-78%,I²=89.3%);并发症率相似,分别为13%和12%,但主要并发症仅见于经皮热消融。作者认为MRgFUS可为骨寡转移的一种有效、安全、无创的治疗选择,需直接比较研究确认。

要点

  • 骨寡转移MRgFUS汇总局部肿瘤控制率84%(95%CI 66-97%),经皮热消融65%(95%CI 51-78%)。
  • 两组并发症率相似(MRgFUS 13% vs 经皮热消融12%),主要并发症仅见于经皮热消融。
  • Meta回归分析未发现技术类型、研究设计、肿瘤及随访的显著预测因素。

核心结论

  • MRgFUS与经皮热消融治疗骨寡转移的有效性和安全性相当,MRgFUS为无创治疗且未引起任何主要并发症;作者认为MRgFUS可为骨寡转移的一种有效、安全、无创的治疗选择,需直接比较研究确认其获益。

研究设计与样本

  • 系统综述与Meta分析,按PICO/PRISMA方案检索PubMed、BioMed Central和Scopus,纳入24篇文章,采用改良Newcastle-Ottawa量表评估文献质量;分别对经皮热消融和MRgFUS进行两项独立的随机效应Meta分析,合并局部肿瘤控制率和并发症率,并进行Meta回归分析。

诊断标准与关键数值

  • MRgFUS汇总局部肿瘤控制率为84%(N=7,95%CI 66-97%,I²=74.7%)。
  • 经皮热消融汇总局部肿瘤控制率为65%(N=17,95%CI 51-78%,I²=89.3%)。
  • MRgFUS汇总并发症率为13%(95%CI 1-32%,I²=81.0%),经皮热消融为12%(95%CI 8-18%,I²=39.9%)。
  • 主要并发症仅见于经皮热消融组。

临床应用与阅片要点

  • 作者认为MRgFUS可为骨寡转移的一种有效、安全、无创的治疗选择。
  • 作者指出需要直接比较研究确认MRgFUS的获益。

局限性

  • MRgFUS数据有限。
  • 缺乏与经皮热消融的直接比较。
  • 需直接比较研究确认MRgFUS的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The percutaneous thermal ablation techniques (pTA) are radiofrequency ablation, cryoablation, and microwave ablation, suitable for the treatment of bone oligometastases. Magnetic resonance-guided focused ultrasound (MRgFUS) is a noninvasive ablation technique.

OBJECTIVES: To compare the effectiveness and safety of MRgFUS and pTA for treating bone oligometastases and their complications.

METHODS: Studies were selected with a PICO/PRISMA protocol: pTA or MRgFUS in patients with bone oligometastases; non-exclusive curative treatment. Exclusion criteria were: primary bone tumor; concurrent radiation therapy; palliative therapy; and absence of imaging at follow-up. PubMed, BioMed Central, and Scopus were searched. The modified Newcastle-Ottawa Scale assessed articles quality. For each treatment (pTA and MRgFUS), we conducted two separate random-effects meta-analyses to estimate the pooled effectiveness and safety. The effectiveness was assessed by combining the proportions of treated lesions achieving local tumor control (LTC); the safety by combining the complications rates of treated patients. Meta-regression analyses were performed to identify any outcome predictor.

RESULTS: A total of 24 articles were included. Pooled LTC rate for MRgFUS was 84% (N = 7, 95% CI 66-97%, I2 = 74.7%) compared to 65% of pTA (N = 17, 95% CI 51-78%, I2 = 89.3%). Pooled complications rate was similar, respectively, 13% (95% CI 1-32%, I2 = 81.0%) for MRgFUS and 12% (95% CI 8-18%, I2 = 39.9%) for pTA, but major complications were recorded with pTA only. The meta-regression analyses, including technique type, study design, tumor, and follow-up, found no significant predictors.

DISCUSSION: The effectiveness and safety of the two techniques were found comparable, even though MRgFUS is a noninvasive treatment that did not cause any major complication. Limited data availability on MRgFUS and the lack of direct comparisons with pTA may affect these findings.

CONCLUSIONS: MRgFUS can be a valid, safe, and noninvasive treatment for bone oligometastases. Direct comparison studies are needed to confirm its promising benefits.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Leporace M, Lancellotta V, Baccolini V, et al. Magnetic resonance-guided focused ultrasound versus percutaneous thermal ablation in local control of bone oligometastases: a systematic review and meta-analysis. Radiol Med. 2024. PMID: 38302831. doi:10.1007/s11547-024-01780-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。